Works about MYELOFIBROSIS
Results: 2095
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries.
- Published in:
- British Journal of Haematology, 2025, v. 206, n. 1, p. 172, doi. 10.1111/bjh.19812
- By:
- Publication type:
- Article
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study.
- Published in:
- Quality of Life Research, 2025, v. 34, n. 3, p. 739, doi. 10.1007/s11136-024-03855-1
- By:
- Publication type:
- Article
Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01235-7
- By:
- Publication type:
- Article
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib.
- Published in:
- Oncology & Therapy, 2025, v. 13, n. 1, p. 165, doi. 10.1007/s40487-024-00322-2
- By:
- Publication type:
- Article
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 241, doi. 10.1007/s00277-025-06204-5
- By:
- Publication type:
- Article
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 295, doi. 10.1007/s00277-025-06191-7
- By:
- Publication type:
- Article
Folate metabolism in myelofibrosis: a missing key?
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 35, doi. 10.1007/s00277-024-06176-y
- By:
- Publication type:
- Article
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
- Published in:
- Wiener Klinische Wochenschrift, 2013, v. 125, n. 7/8, p. 196, doi. 10.1007/s00508-013-0345-z
- By:
- Publication type:
- Article
Association of Extensive Brain Calcifications, Myelofibrosis, and Retinopathy in a 12-Year-Old Child.
- Published in:
- Pediatric & Developmental Pathology, 2008, v. 11, n. 2, p. 148, doi. 10.2350/06-03-0061.1
- By:
- Publication type:
- Article
Feline myelonecrosis and myelofibrosis: 22 cases 1996–2006.
- Published in:
- Comparative Clinical Pathology, 2007, v. 16, n. 3, p. 181, doi. 10.1007/s00580-007-0669-z
- By:
- Publication type:
- Article
Relationship Between Serum Periostin Level and Bone Marrow Fibrosis in Newly Diagnosed Multiple Myeloma Patients.
- Published in:
- Namık Kemal Tıp Dergisi, 2023, v. 11, n. 2, p. 158, doi. 10.4274/nkmj.galenos.2023.34936
- By:
- Publication type:
- Article
Myeloproliferative Cancers: Treatment Prospects for Rare Diseases.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 22, p. 1694, doi. 10.1093/jnci/djs480
- By:
- Publication type:
- Article
Myelofibrosis treatment history and future prospects.
- Published in:
- Egyptian Journal of Internal Medicine, 2022, v. 34, n. 1, p. 1, doi. 10.1186/s43162-022-00169-x
- By:
- Publication type:
- Article
Advances in the Therapy of Chronic Idiopathic Myelofibrosis.
- Published in:
- Oncologist, 2006, v. 11, n. 8, p. 929, doi. 10.1634/theoncologist.11-8-929
- By:
- Publication type:
- Article
Classification of Common Variable Immunodeficiency Using Measurement of B-cell Subsets in Moroccan Patients.
- Published in:
- Turkish Journal of Immunology, 2023, v. 11, n. 1, p. 29, doi. 10.4274/tji.galenos.2023.36854
- By:
- Publication type:
- Article
Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms– Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
- Published in:
- Contributions / Prilozi (1857-9345), 2023, v. 44, n. 3, p. 57, doi. 10.2478/prilozi-2023-0047
- By:
- Publication type:
- Article
From Driver Mutations to Genomic Classification: Current & Future Perspectives on Myeloproliferative Neoplasms.
- Published in:
- Malaysian Journal of Medicine & Health Sciences, 2021, v. 17, n. 1, p. 170
- By:
- Publication type:
- Article
Rare Cases of Haemoglobin Variant Presented with Isolated Erythrocytosis.
- Published in:
- Malaysian Journal of Medicine & Health Sciences, 2020, v. 16, n. Supp9, p. 114
- By:
- Publication type:
- Article
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 29, doi. 10.1007/s13555-021-00624-7
- By:
- Publication type:
- Article
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01211-1
- By:
- Publication type:
- Article
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01169-6
- By:
- Publication type:
- Article
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01151-2
- By:
- Publication type:
- Article
Are thrombosis, progression, and survival in ET predictable?
- Published in:
- 2024
- By:
- Publication type:
- Letter
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01052-4
- By:
- Publication type:
- Article
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01031-9
- By:
- Publication type:
- Article
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01028-4
- By:
- Publication type:
- Article
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01029-3
- By:
- Publication type:
- Article
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00991-2
- By:
- Publication type:
- Article
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00987-y
- By:
- Publication type:
- Article
One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00972-x
- By:
- Publication type:
- Article
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00968-7
- By:
- Publication type:
- Article
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00947-y
- By:
- Publication type:
- Article
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00922-7
- By:
- Publication type:
- Article
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00887-7
- By:
- Publication type:
- Article
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00869-9
- By:
- Publication type:
- Article
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00878-8
- By:
- Publication type:
- Article
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00876-w
- By:
- Publication type:
- Article
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00867-x
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00834-6
- By:
- Publication type:
- Article
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00829-3
- By:
- Publication type:
- Article
Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00824-8
- By:
- Publication type:
- Article
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00800-2
- By:
- Publication type:
- Article
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00786-x
- By:
- Publication type:
- Article
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00780-9
- By:
- Publication type:
- Article
Breakthrough infections in MPN-COVID vaccinated patients.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00749-8
- By:
- Publication type:
- Article
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00743-0
- By:
- Publication type:
- Article
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00718-1
- By:
- Publication type:
- Article
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00713-6
- By:
- Publication type:
- Article
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
- Published in:
- 2022
- By:
- Publication type:
- Letter
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-022-00609-5
- By:
- Publication type:
- Article